Wenliang Song is a Cardiology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
593 Eddy St
Providence, RI 029034923
Telephone
401-444-5891Provider last certified this registry record 11 Oct 2023.
Clinical trials
- 2-HOBA Supplementation in People With Elevated Lipoprotein(a)
Sponsor: The Miriam Hospital
- Differential Thrombogenesis by EPA and DHA Mediated by HDL
Sponsor: The Miriam Hospital
- Biosynthesis of PGD2 in Vivo
Sponsor: University of Pennsylvania
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%PCSK9 Inhibitor36.4%Repatha Sureclick100%Part D<11 patientsCholesterol absorption inhibitor33.8%Ezetimibe100%Part D≥13 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Differential thrombogenesis effects of EPA and DHA mediated by HDL
Miriam Hospital
FY2026$514,851R01HL159204 - Differential thrombogenesis effects of EPA and DHA mediated by HDL
Miriam Hospital
FY2025$526,228R01HL159204 - Differential thrombogenesis effects of EPA and DHA mediated by HDL
Miriam Hospital
FY2024$516,085R01HL159204
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”